Every year, tens of thousands of Maryland residents live with opioid use disorder without receiving medication-assisted treatment, not because effective options don’t exist, but because starting feels complicated. Brixadi injections in Maryland change that equation by turning a daily struggle into a scheduled appointment. This guide walks through everything you need to know to evaluate whether Brixadi is the right fit, how coverage works, what the first appointment actually looks like, and where to go from here.
What Brixadi Is and How It Works
A 2022 Cochrane review of 31 randomized controlled trials involving more than 5,500 participants confirmed that buprenorphine maintenance treatment reduces illicit opioid use and keeps patients in treatment significantly longer than placebo or no medication. That foundation matters because it’s what Brixadi is built on. Brixadi is a subcutaneous extended-release buprenorphine injection, administered by a provider in the office on either a weekly or monthly schedule, depending on where you are in treatment.
The plain-English mechanism is straightforward. Sublingual buprenorphine (film or tablet) dissolves under your tongue and enters the bloodstream quickly, creating a peak concentration followed by a gradual decline. By the time you’re due for the next dose, levels have dropped enough that cravings can return. Brixadi works differently. The subcutaneous formulation releases buprenorphine slowly from the injection depot over the course of days or weeks, maintaining a steady concentration in the bloodstream. No peaks. No troughs. No window where craving intensity spikes because your last dose is wearing off. In practice, this means no pharmacy trips, no daily dosing schedule to manage, and no possibility of a missed dose disrupting your stability.
How Brixadi Differs from Suboxone and Other Buprenorphine Forms
A 2019 pharmacokinetics study published in Clinical Pharmacokinetics comparing subcutaneous extended-release buprenorphine to sublingual buprenorphine found that the injectable formulation produced more consistent plasma concentrations with significantly lower peak-to-trough fluctuation. That variability in sublingual formulations isn’t a flaw in the medication; it’s a property of the delivery route. Films and tablets work well for patients who can reliably take a daily dose at the same time without disruption. The injectable format serves a different clinical reality.
Suboxone combines buprenorphine with naloxone to deter misuse and is administered daily. Brixadi contains only buprenorphine and is administered by a provider, which removes the diversion risk without the need for the naloxone component. If you’re exploring how the sublingual weekly option compares before committing to a format, that context is worth understanding before your first provider conversation.
The practical takeaway: if daily adherence is the friction point in your treatment history, the injectable format addresses that friction at the source. The formulation matches the lifestyle, not the other way around.
The Two Dosing Schedules: Weekly and Monthly
The FDA approved Brixadi in two schedules: weekly injections and monthly injections. The Phase 3 double-blind trial (NCT02651584) that supported FDA approval demonstrated that both schedules produced sustained reductions in opioid use and high rates of treatment retention across a 24-week study period. Providers typically use the weekly schedule during the early phase of treatment to establish stability, then transition to the monthly schedule once that stability is confirmed.
For most patients, the first 30 days look like this: an intake assessment and first injection at the initial appointment, a return visit the following week for the second injection and a brief clinical check-in, and two more weekly visits before the conversation about transitioning to monthly dosing begins. The monthly schedule doesn’t require doing anything differently on your end. You come in once a month, the provider administers the injection, and the medication handles the rest. Understanding how the weekly injection cycle works in detail helps set realistic expectations for that first month of treatment.
Who Qualifies for Brixadi Treatment in Maryland
According to SAMHSA’s 2023 National Survey on Drug Use and Health, Maryland had an estimated 6.8% rate of opioid misuse among adults aged 18 and older, one of the higher state-level figures in the Mid-Atlantic region. The diagnostic threshold for Brixadi candidacy is moderate-to-severe opioid use disorder as defined by DSM-5 criteria, which means at least four of eleven diagnostic indicators present within a 12-month period.
Fentanyl dependence qualifies. This is a question many patients ask directly, and the answer is unambiguous: fentanyl is an opioid, and opioid use disorder is the diagnosis, regardless of the specific substance. The same applies to heroin, prescription painkillers, or any combination. What providers look for is evidence of physical opioid dependence and tolerance, because Brixadi is started after stabilization, not during acute withdrawal. The one question worth asking on the first call: “Does your intake process confirm opioid tolerance before scheduling the first injection?” A yes confirms you’re talking to a provider who follows FDA prescribing guidance on patient selection.
Patients Managing Co-Occurring Mental Health Conditions
A 2020 study in the Journal of Substance Abuse Treatment reviewing data from 27,000 patients in treatment for OUD found that approximately 65% had at least one co-occurring mental health diagnosis, most commonly anxiety disorders, major depression, and PTSD. Co-occurring conditions don’t disqualify you from Brixadi treatment. In fact, research published in JAMA Psychiatry consistently shows that integrated care, meaning MAT and mental health treatment delivered together rather than sequentially, produces better retention rates and lower relapse rates than treating each condition separately.
At the clinic level, integrated care means your prescribing provider and your counseling team communicate about your care plan rather than operating independently. When evaluating a clinic, ask whether behavioral health services are available on-site or coordinated through a warm referral. The distinction matters because “we can refer you” and “we coordinate directly with your counselor” describe very different patient experiences.
When Brixadi May Not Be the Right Starting Point
The FDA prescribing information for Brixadi identifies several contraindications that a provider will screen for during the intake assessment. Acute or severe hepatic impairment is a contraindication, because buprenorphine is hepatically metabolized and impaired liver function affects how the medication is processed. A known hypersensitivity to buprenorphine rules out the medication entirely. Certain injection-site conditions, including active infection or significant scarring at the abdomen or upper arm, affect whether the subcutaneous route is appropriate.
Beyond hard contraindications, there’s a clinical preference point worth understanding: Brixadi is approved for patients who are already opioid-tolerant. It is not approved for opioid-naive patients. If you have not recently been using opioids, sublingual buprenorphine is the more appropriate starting point. The screening question providers use to determine the right first step is essentially this: when did you last use opioids, and are you currently experiencing withdrawal symptoms? The answers to those two questions guide the induction decision more than any other factor.
How Maryland’s Insurance Landscape Covers Brixadi
A 2023 report from the Maryland Department of Health found that Medicaid covered more than 60% of individuals receiving substance use disorder treatment in the state. For MAT specifically, Maryland Medicaid has expanded coverage substantially in recent years, but the specifics of prior authorization vary by medication and by the managed care organization administering the benefit. The action to take before the first appointment: call the billing team at the clinic and ask, “Does my plan require prior authorization for Brixadi, and what documentation do you need from me?” That single question prevents the most common first-appointment delay.
Maryland Medicaid Coverage and Prior Authorization
Maryland Medicaid covers buprenorphine-based MAT, including extended-release injectable formulations, under its behavioral health benefit. According to SAMHSA’s Treatment Improvement Protocol TIP 63, prior authorization for injectable buprenorphine typically requires documentation of a DSM-5 OUD diagnosis, evidence of opioid dependence, and the prescriber’s DEA registration. Some Maryland Medicaid managed care organizations require documentation of prior treatment attempts, though this requirement has been reduced or eliminated for injectable buprenorphine in several recent policy updates.
If prior authorization is denied, you have the right to appeal. The standard appeal pathway requires the prescribing provider to submit a clinical letter documenting medical necessity, including the rationale for the injectable formulation over sublingual alternatives. Turnaround on standard appeals is typically 30 days; expedited appeals for urgent clinical need can be resolved within 72 hours. Ask the clinic’s billing team whether they manage the appeal process on your behalf. Most established MAT practices handle this routinely.
Commercial Insurance and Out-of-Pocket Costs
Commercial insurers operating in Maryland, including CareFirst, Aetna, and BlueCross BlueShield plans, generally cover buprenorphine-based MAT under the mental health and substance use disorder benefit parity requirements established by the Mental Health Parity and Addiction Equity Act. Coverage for injectable buprenorphine specifically varies by plan tier and formulary. A 2022 KFF analysis of out-of-pocket costs for MAT found that high-deductible health plans create meaningful adherence barriers in the first 90 days of treatment, before the deductible is met.
Braeburn, the manufacturer of Brixadi, offers a patient assistance program for commercially insured patients who meet income criteria, as well as a co-pay assistance card that reduces out-of-pocket costs at the time of the injection. If you’re on a high-deductible plan, apply for the co-pay assistance before the first appointment rather than after. The application is administered through the prescribing provider’s office in most cases.
No Insurance? What Maryland Patients Can Do
Maryland’s Behavioral Health Administration funds treatment access through a network that includes Federally Qualified Health Centers, Opioid Intervention Teams, and state-funded treatment slots at licensed programs. HRSA data from 2023 shows that Maryland has 51 FQHCs operating across 295 delivery sites, and most offer MAT on a sliding-fee scale tied to household income. For uninsured patients, the sliding-fee schedule means the cost of treatment is calculated based on your income, not a flat rate.
The starting point if you have no insurance: call the clinic directly and say you’re uninsured. Ask whether they accept patients on a sliding-fee scale or can connect you to a state-funded MAT slot. That one call, before anything else, tells you whether the clinic can serve you and what the cost structure looks like. Finding a location that fits your coverage situation is easier when you know which questions to ask upfront.
What to Expect at a Brixadi Appointment in Maryland
A 2021 study in Drug and Alcohol Dependence tracking 1,200 patients initiating buprenorphine treatment found that logistical friction, including appointment complexity, wait times, and unclear intake processes, was among the top three predictors of dropout in the first 90 days. The appointment experience isn’t incidental to treatment success. It’s part of it.
The intake appointment at an established MAT clinic typically runs 60 to 90 minutes. It includes a clinical assessment covering your substance use history and current medications, a urine drug screen, informed consent documentation, and the first injection. The injection itself is subcutaneous, meaning it goes just under the skin rather than into muscle, at the abdomen or upper arm. Most patients describe the sensation as minimal. After the injection, a brief monitoring period confirms there are no immediate adverse reactions before you leave.
The Induction Process: From First Call to First Injection
The intake sequence at most Maryland MAT clinics follows a predictable pattern: phone intake and insurance verification, scheduling the clinical assessment, completing the assessment on the day of the appointment, and receiving the first injection the same day if clinically appropriate. The American Society of Addiction Medicine (ASAM) criteria guide induction decisions, with the key variable being confirmation of opioid tolerance and absence of acute withdrawal severe enough to require inpatient stabilization first.
The single piece of documentation that most commonly delays a first injection is proof of identity and insurance. Arriving without a government-issued ID or without your insurance card, or without the member ID number if the physical card isn’t available, extends the process by 24 to 48 hours in most cases. Have those two items ready before the call to schedule. Everything else, including the clinical assessment itself, happens at the appointment.
Managing Injection-Site Reactions and Early Side Effects
The RECOVER trial data and Brixadi product labeling report that injection-site reactions are the most common adverse event, occurring in approximately 30 to 40% of patients. The typical reactions are nodule formation at the injection site, localized bruising, and tenderness. These are time-limited and generally resolve within one to two weeks without intervention. They’re common enough that providers describe them to patients routinely during the consent process, not because they’re serious, but because patients who expect them don’t misinterpret them as signs that something has gone wrong.
The three things to monitor in the 48 hours after an injection: localized swelling or firmness at the injection site (expected), skin color changes such as bruising (expected), and any spreading redness, warmth, or discharge (not expected, and worth a same-day call to the clinic). Fever following an injection always warrants contact. Everything else in that first 48-hour window is almost certainly normal.
Counseling, Drug Testing, and What Else Is Required
SAMHSA’s Treatment Improvement Protocol TIP 43 establishes that pharmacotherapy combined with counseling produces better outcomes than either alone for OUD. Maryland-licensed MAT programs reflect this in their treatment requirements. Most clinics require participation in counseling as a condition of continued prescribing, typically one individual counseling session per week during the early phase of treatment and reduced frequency as stability is established.
Drug screening is standard. Urine screens at intake and at follow-up appointments confirm treatment adherence and identify any co-occurring substance use that affects the care plan. These aren’t punitive; they’re clinical data. On the question of what’s mandatory versus strongly recommended: counseling is generally a program requirement. Peer support groups are strongly recommended and associated with better long-term outcomes but are typically not required. Understanding what a full treatment program actually includes before your first appointment removes the guesswork about what’s expected of you.
Maryland Locations Where Brixadi Is Available
SAMHSA’s 2024 treatment locator data indicates that Maryland has more than 400 providers with active buprenorphine prescribing waivers, though the geographic distribution is uneven, with higher concentrations in the Baltimore-Washington corridor and lower access in rural Western Maryland and the Eastern Shore. MD M.A.T.T. operates five Maryland locations providing Brixadi: Baltimore, College Park, Linthicum Heights, Nottingham, and Owings Mills. Each location administers injections in office, with scheduling and insurance coordination handled by the clinical team rather than requiring patients to navigate that process independently.
Appointment availability, telehealth intake options, and walk-in access vary by location. The most direct way to match yourself to the right site: call with your zip code and insurance type, and ask which location has the earliest available intake appointment. For patients near the I-695 corridor, the Nottingham and Owings Mills locations both serve the greater Baltimore area. For patients in Prince George’s County or southern Maryland, College Park is the closest access point. Knowing how to identify the right clinic match before you call makes that first conversation faster.
Telehealth Intake Options Across Maryland
Following the DEA’s 2023 updated guidance on telemedicine prescribing of buprenorphine, providers with an existing DEA registration can conduct the initial assessment via telehealth for patients who cannot attend in person, with certain conditions met. The intake assessment, clinical history review, and prescription authorization can all happen through a video visit. The injection itself cannot. Brixadi is a subcutaneous injection administered by a provider, so at minimum the injection appointments require an in-person visit.
For patients in rural Maryland counties, those without transportation, or those whose work schedules make in-person intake difficult, the telehealth pathway means treatment can begin without a 90-minute commute to the first appointment. The injection visit still requires physically being at a clinic location, but that’s a single scheduled appointment, not a daily obligation. If you’re weighing how to start given a transportation barrier, ask specifically about telehealth intake when you call.
How Family Members Can Help Someone Start
A 2019 NIDA-funded study of 1,847 adults in OUD treatment found that patients with consistent family involvement in early treatment had a 34% higher 90-day retention rate than those without it. Family support doesn’t require any clinical training. It requires showing up in specific, practical ways at the right moments.
Before the first call, the most useful thing a family member can do is gather the insurance information: the plan name, member ID, and the number on the back of the card. That information is the first thing the billing team needs, and having it ready at the start of the call removes a common reason people say they’ll call later and don’t. During early treatment, the highest-value support is reliable transportation to the first few injection appointments, because those early visits establish the treatment relationship that predicts retention. What to avoid: framing the decision to start treatment as conditional (“I’ll support you if you go today”) or using language that implies shame about the diagnosis. A 2020 study in Addictive Behaviors found that shame-inducing interactions in the 30 days before treatment initiation were among the strongest predictors of dropout in the first two weeks.
The one action for this week: locate the insurance card and confirm whether the plan is Medicaid or commercial before reaching out to a clinic. That takes five minutes and removes the most common logistical barrier to a first appointment.
Common Reasons Patients Delay Starting and How to Resolve Them
A 2023 analysis by the Substance Abuse and Mental Health Services Administration examining treatment gap causes across 22 states found that the four most commonly cited reasons for not starting MAT were stigma, cost uncertainty, logistical complexity, and fear of withdrawal during induction. Each of these has a direct, resolvable answer.
Stigma is real, and it’s also inconsistent with the evidence. The American Society of Addiction Medicine designates medications for opioid use disorder, including buprenorphine, as the standard of care. Not one option among many. The standard. That means starting Brixadi isn’t a compromise or a crutch; it’s the medically recommended treatment for moderate-to-severe OUD, supported by decades of clinical trial data.
Cost uncertainty resolves with one phone call. Maryland Medicaid covers MAT. Commercial plans are required by federal parity law to cover it. For uninsured patients, FQHCs and sliding-fee programs exist specifically to fill that gap. The billing question to ask is not “do you accept my insurance?” but “can your team verify my coverage and tell me my out-of-pocket cost before the first appointment?” A clinic that handles this proactively is a clinic worth scheduling with.
Logistical complexity is largely addressed by telehealth intake. The assessment doesn’t require showing up somewhere before you know whether the process is right for you. Fear of withdrawal during induction comes from conflating when Brixadi is appropriate with what the medication does. Brixadi is started after opioid tolerance is confirmed and outside of acute withdrawal, not during it. The medication stabilizes you. It doesn’t destabilize you to get there.
The barrier most likely to cause a delay is the simplest one to clear: not knowing which clinic to call. Using a provider search specific to Maryland narrows that down before you pick up the phone.
What to Try This Week
According to SAMHSA’s 2023 data, fewer than 20% of people with opioid use disorder received any form of medication-assisted treatment in the previous year. The gap isn’t lack of effective options. It’s the distance between knowing treatment exists and making the first contact.
The single move that starts the process: call and confirm your insurance is accepted, or ask about the sliding-fee schedule if you’re uninsured. That call takes less than five minutes. It answers the cost question, confirms appointment availability, and tells you exactly what to bring to the intake visit. Everything else, the assessment, the injection, the follow-up schedule, happens after that call, not before it.
Brixadi is administered in the office on a schedule that fits around your life, not the other way around. The weekly and monthly dosing options exist precisely because treatment looks different at week two than it does at month six, and a treatment program designed with that flexibility in mind starts with one phone call.